Allergy news and updates

Podcast 8 Dec 2023

Can worms provide treatments for some diseases?

U.S. company Holoclara is looking to tackle diseases through the development of worm-derived therapeutics. Allergic and autoimmune diseases were first described in the early 1900s, which Holoclara said is the same time that gut-resident worms such as the roundworm, Caenorhabditis elegans, were removed from people in industrialized countries. The company, led by CEO Andrea Choe, […]

December 8, 2023

In Depth 9 Jun 2023

Enhancing canine wellness: The promise of immunotherapy for dogs

Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health and extend their lives. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight […]

June 9, 2023 - 8 minutesmins - By Willow Shah-Neville

In Depth 11 May 2023

Battling food allergies: emerging immunotherapies

While for most individuals, picking a restaurant to dine at could simply be based on what they might be craving at the moment, for about one to five per cent of the world’s population, this is a well-thought-out decision that involves ensuring there wouldn’t be any cross-contamination in the food which is bound to trigger […]

May 11, 2023 - 9 minutesmins - By Roohi Mariam Peter

In Depth 2 May 2023

The future of asthma treatment: is a cure possible?

For around 300 million people in the world, whipping out their inhaler – a medical device that delivers medicine to the lungs to open up narrowed airways – before puffing medicine into their mouth, is a typical response to wheezing, worsened by an asthma attack. While inhalers offer momentary relief, it is, however, no cure. […]

May 2, 2023 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 8 Dec 2022

Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials

Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, which aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

Interview 19 Aug 2022

How re-engineering antibodies can prevent allergies

The California startup IgGenix is aiming to re-engineer antibodies that mediate allergic responses into antibodies that can block this response. We spoke with IgGenix’s CEO Jessica Grossman and CTO Derek Croote to understand the potential of such a therapy. Allergies are overreactions of the immune system to foreign substances that are normally harmless. Worldwide, and […]

August 19, 2022 - 9 minutesmins - By Omnia Ibrahim

News and Trends 22 Jun 2022

From mugwort allergy to an effective vaccine?

A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the development of the world’s first vaccine. Mugwort (Artemisia vulgaris) poses a serious problem for some people with allergies in places where the plant is common […]

June 22, 2022 - 2 minutesmins - By Jim Cornall

peanut allergy treatment DBV Technologies Aimmune Viaskin Palforzia

News and Trends 14 Apr 2021

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a comeback plan that could carve it a niche in the peanut allergy treatment market. The French biotech firm DBV is coming back from a snub by […]

April 14, 2021 - 5 minutesmins - By External Contributor

Best in Biotech 8 May 2019

Top 10 Biotechs in Lausanne

The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […]

May 8, 2019 - 7 minutesmins - By David Cox

News and Trends 18 Mar 2019

Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial

Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the announcement, the shares of Allergy Therapeutics on the London Stock Exchange dropped over 40% within two hours. The phase III trial enrolled 582 people across […]

March 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

autoimmune disorder eosinophilic esophagitis allergy milk calypso biotech

News and Trends 20 Feb 2019

Inflammatory Disease Treatment Backed by €20M Series A

The Swiss company Calypso Biotech has raised a sizeable €20M to fund its immunotherapy for an allergy-related inflammatory disease. The Series A round will help to develop Calypso’s antibody treatment for eosinophilic esophagitis, a condition where patients have an inflamed esophagus and difficulty swallowing. This condition is often linked with allergies to food, such as […]

February 20, 2019 - 2 minutesmins - By Jonathan Smith

desentum hay fever allergy vaccine espoo

Startup Scout 7 Dec 2018

This Hypoallergenic Vaccine Could Alleviate Hay Fever Faster Than Approved Vaccines

We decided to make a visit to Espoo, Finland, this week, to visit Desentum. The company is developing allergy vaccines that could be safer and faster than approved vaccines. Mission: To make a vaccine that decreases the time taken to reduce allergies compared with approved vaccines, which contain the natural allergen. Desentum plans to do […]

December 7, 2018 - 4 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us